Valar Labs, a developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, secures $22million in series A round funding.
With participation from Pear VC, DCVC and Andreessen Horowitz (a16z) Bio + Health led the round. James Hardiman, General Partner at DCVC, and Vineeta Agarwala, MD, PhD, General Partner at a16z Bio + Health, will be joining the board of directors.
Read also – [Funding News] NYC-based Authentic Secures $11Million in Series A Round Funding
The money will be used by the business to increase operations and R&D. Valar Labs is a precision medicine startup led by Viswesh Krishna, CEO, and COO Damir Vrabac. The company develops computational histology AI tests to predict response to cancer therapies.
It seeks to provide each patient and doctor the power to decide which course of action is best for them based on their tumour biology. Vesta, the company’s test for bladder cancer, offers comprehensive risk stratification for progression and recurrence and may identify which patients are unlikely to benefit from BCG therapy.
About Valar Labs
Valar Labs was founded at the intersection of AI and oncology, with a belief that pathology is an untapped modality in cancer care. They built their company around a vision of using AI and the rich information in pathology slides to help physicians and patients make the best possible decisions around cancer treatments.
